Amicus Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Amicus Therapeutics es Brad Campbell , nombrado en Jan 2015, tiene una permanencia de 9.83 años. compensación anual total es $8.20M, compuesta por 8.5% salario y 91.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.3% de las acciones de la empresa, por valor de $8.44M. La antigüedad media del equipo directivo y de la junta directiva es de 7.7 años y 6.3 años, respectivamente.
Información clave
Brad Campbell
Chief Executive Officer (CEO)
US$8.2m
Compensación total
| Porcentaje del salario del CEO | 8.5% |
| Permanencia del CEO | 9.8yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 7.7yrs |
| Promedio de permanencia en la Junta Directiva | 6.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden
Nov 10
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$120m |
| Mar 31 2024 | n/a | n/a | -US$147m |
| Dec 31 2023 | US$8m | US$699k | -US$152m |
| Sep 30 2023 | n/a | n/a | -US$174m |
| Jun 30 2023 | n/a | n/a | -US$185m |
| Mar 31 2023 | n/a | n/a | -US$204m |
| Dec 31 2022 | US$9m | US$591k | -US$237m |
| Sep 30 2022 | n/a | n/a | -US$264m |
| Jun 30 2022 | n/a | n/a | -US$281m |
| Mar 31 2022 | n/a | n/a | -US$270m |
| Dec 31 2021 | US$5m | US$551k | -US$250m |
| Sep 30 2021 | n/a | n/a | -US$239m |
| Jun 30 2021 | n/a | n/a | -US$252m |
| Mar 31 2021 | n/a | n/a | -US$254m |
| Dec 31 2020 | US$5m | US$516k | -US$277m |
| Sep 30 2020 | n/a | n/a | -US$295m |
| Jun 30 2020 | n/a | n/a | -US$293m |
| Mar 31 2020 | n/a | n/a | -US$325m |
| Dec 31 2019 | US$4m | US$501k | -US$356m |
| Sep 30 2019 | n/a | n/a | -US$345m |
| Jun 30 2019 | n/a | n/a | -US$442m |
| Mar 31 2019 | n/a | n/a | -US$419m |
| Dec 31 2018 | US$3m | US$468k | -US$349m |
| Sep 30 2018 | n/a | n/a | -US$340m |
| Jun 30 2018 | n/a | n/a | -US$293m |
| Mar 31 2018 | n/a | n/a | -US$279m |
| Dec 31 2017 | US$2m | US$450k | -US$284m |
Compensación vs. Mercado: La compensación total ($USD8.20M) de Brad está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.63M).
Compensación vs. Ingresos: La compensación de Brad ha sido consistente con los resultados de la empresa en el último año.
CEO
Brad Campbell (48 yo)
9.8yrs
Permanencia
US$8,202,366
Compensación
Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 9.8yrs | US$8.20m | 0.30% $ 8.4m | |
| Chief Financial Officer | 1.3yrs | US$3.27m | 0.0048% $ 135.4k | |
| Chief Legal Officer & Corporate Secretary | 8.8yrs | US$4.08m | 0.064% $ 1.8m | |
| Chief People Officer | 6.1yrs | US$3.21m | 0.046% $ 1.3m | |
| Chief Development Officer | no data | US$3.67m | 0.080% $ 2.3m | |
| Chief Accounting Officer & Controller | 6.7yrs | sin datos | 0.025% $ 703.8k | |
| Chief Science Officer | no data | sin datos | sin datos | |
| Senior Director of Investor Relations | no data | sin datos | sin datos | |
| Global Chief Compliance & Risk Officer | 9.3yrs | sin datos | sin datos | |
| Head of Global Corporate Communications | no data | sin datos | sin datos | |
| Chief Patient Advocate | 9.2yrs | sin datos | sin datos | |
| Chief Program Officer | 4.5yrs | sin datos | sin datos |
7.7yrs
Permanencia media
54.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de FOLD es experimentado (7.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 6.4yrs | US$8.20m | 0.30% $ 8.4m | |
| Independent Director | 5.4yrs | US$391.25k | 0.026% $ 740.2k | |
| Independent Director | 3.9yrs | US$391.25k | 0.0098% $ 279.9k | |
| Independent Director | 18.4yrs | US$407.07k | 0.025% $ 714.0k | |
| Independent Director | 15.1yrs | US$401.25k | 0.017% $ 482.7k | |
| Chairman & Lead Independent Director | 20.8yrs | US$426.25k | 0.025% $ 714.0k | |
| Independent Director | 3.4yrs | US$390.00k | 0.0080% $ 229.0k | |
| Independent Director | 6.2yrs | US$397.50k | 0.024% $ 695.8k |
6.3yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de FOLD se considera experimentada (6.3 años de antigüedad promedio).